ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock?

AbbVie (ABBV) continued its acquisition spree with the announcement of a definitive agreement to acquire private biotech Nimble Therapeutics, which will add the latter’s lead pipeline candidate, an oral peptide IL23R inhibitor in preclinical development for psoriasis. The acquisition will strengthen AbbVie’s immunology pipeline.Nimble is also making oral peptide-based therapeutics for autoimmune diseases leveraging its proprietary peptide synthesis platform. To acquire Nimble, AbbVie will make a cash paymen ...